Logo
x

Search

Subscribe Now

Calliditas Therapeutics

Calliditas Therapeutics’ Tarpeyo Receives Full US FDA’s Approval for IgA Nephropathy to Reduce the Loss of Kidney Function

Calliditas Therapeutics’ Tarpeyo Receives Full US FDA’s Approval for IgA Nephropathy to Reduce the Loss of Kidney Function

  • December 21, 2023
Calliditas Therapeutics Launches P-II Trial for Setanaxib in Alport Syndrome

Calliditas Therapeutics Launches P-II Trial for Setanaxib in Alport Syndrome

  • November 30, 2023
Calliditas Therapeutics Reports sNDA Submission to the US FDA for Tarpeyo to Treat Primary IgA Nephropathy

Calliditas Therapeutics Reports sNDA Submission to the US FDA for Tarpeyo to Treat Primary IgA Nephropathy

  • June 21, 2023
Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

  • January 9, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.